ES2161085T3 - Formulaciones que contienen oxaliplatino. - Google Patents

Formulaciones que contienen oxaliplatino.

Info

Publication number
ES2161085T3
ES2161085T3 ES99301412T ES99301412T ES2161085T3 ES 2161085 T3 ES2161085 T3 ES 2161085T3 ES 99301412 T ES99301412 T ES 99301412T ES 99301412 T ES99301412 T ES 99301412T ES 2161085 T3 ES2161085 T3 ES 2161085T3
Authority
ES
Spain
Prior art keywords
formulations containing
containing oxaliplatin
oxaliplatin
procedure
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99301412T
Other languages
English (en)
Inventor
Nicholas H Anderson
Ross Blundell
Stephen Brown
David A England
Martin R Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10827600&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2161085(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2161085T3 publication Critical patent/ES2161085T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A FORMULACIONES FARMACEUTICAMENTE ESTABLES DE SOLUCION DE OXALIPLATINA, AL PROCEDIMIENTO DE USO DE LAS MISMAS EN EL TRATAMIENTO DE LOS TUMORES CANCEROSOS, A LOS PROCEDIMIENTOS PARA LA PREPARACION DE TALES FORMULACIONES Y A UN PROCEDIMIENTO PARA ESTABILIZAR SOLUCIONES DE OXALIPLATINA.
ES99301412T 1998-02-25 1999-02-25 Formulaciones que contienen oxaliplatino. Expired - Lifetime ES2161085T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9804013.2A GB9804013D0 (en) 1998-02-25 1998-02-25 Formulations

Publications (1)

Publication Number Publication Date
ES2161085T3 true ES2161085T3 (es) 2001-11-16

Family

ID=10827600

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99301412T Expired - Lifetime ES2161085T3 (es) 1998-02-25 1999-02-25 Formulaciones que contienen oxaliplatino.

Country Status (28)

Country Link
US (1) US6306902B1 (es)
EP (1) EP0943331B1 (es)
JP (1) JP4430229B2 (es)
KR (1) KR20010041182A (es)
CN (1) CN1152718C (es)
AR (1) AR015524A1 (es)
AT (1) ATE202472T1 (es)
AU (1) AU757101B2 (es)
BR (1) BR9908273A (es)
CA (1) CA2261500C (es)
CZ (1) CZ302196B6 (es)
DE (1) DE69900162T2 (es)
DK (1) DK0943331T3 (es)
ES (1) ES2161085T3 (es)
GB (1) GB9804013D0 (es)
GR (1) GR3036646T3 (es)
GT (1) GT199900019A (es)
HK (1) HK1036405A1 (es)
HU (1) HU224611B1 (es)
IL (1) IL137772A (es)
MX (1) MXPA00008195A (es)
NO (1) NO329900B1 (es)
PL (1) PL197948B1 (es)
PT (1) PT943331E (es)
RU (1) RU2207857C2 (es)
UA (1) UA70316C2 (es)
WO (1) WO1999043355A2 (es)
ZA (1) ZA991489B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
MXPA01003799A (es) * 1998-10-14 2003-06-09 Debiopharm Sa Empaque para preparacion de oxaliplatino.
US7070796B1 (en) 1999-08-30 2006-07-04 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation for parenteral administration
KR100688217B1 (ko) * 1999-08-30 2007-02-28 데비오 팜 소시에떼 아노님 비경구 투여용의 약학적으로 안정된 옥살리백금 약학제제 및 그 조제방법
WO2002047725A2 (fr) * 2000-12-12 2002-06-20 Debiopharm S.A. Preparation pharmaceutique d'oxaliplatine pour administration par voie parenterale et procede d'obtention de ladite preparation
WO2002069959A1 (fr) 2001-03-02 2002-09-12 Debiopharm S.A. Dispositif de conditionnement d'une solution d'oxaliplatine
EP1404689A1 (en) 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
DE112004001563T5 (de) * 2003-08-28 2006-07-27 Mayne Pharma Ltd. Säure-haltige Oxaliplatin-Formulierungen
GB2441445B (en) * 2003-08-28 2008-04-23 Mayne Pharma Ltd Acid containing oxaliplatin formulation
CZ300795B6 (cs) * 2003-09-02 2009-08-12 Pliva-Lachema A. S. Farmaceutická kompozice a zpusob její výroby
JP2007504177A (ja) * 2003-09-02 2007-03-01 プリヴァ−ラケマ，エー．エス． 医薬組成物、その製造方法及び治療上の使用
CA2547275A1 (en) 2003-11-25 2005-06-09 Platco Technologies (Proprietary) Limited Platinum(ii) complexes, preparation and use
CN100471493C (zh) * 2003-12-17 2009-03-25 梅比欧法姆股份有限公司 含有奥沙利铂的脂质体制剂
WO2005102312A1 (en) * 2004-04-27 2005-11-03 Mayne Pharma Limited Concentrated oxaliplatin solutions
WO2006024897A1 (en) 2004-09-01 2006-03-09 Platco Technologies (Proprietary) Limited Preparation of platinum(ii) complexes
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
DE102004063764A1 (de) * 2004-12-29 2006-07-13 Hexal Ag Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2006103691A1 (en) * 2005-03-28 2006-10-05 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (ii) antitumour agents
US7605282B2 (en) * 2005-04-09 2009-10-20 Vuab Pharma A.S. Process for the preparation of an oxaliplatin preparation
DE102005038347A1 (de) * 2005-08-11 2007-02-15 Hexal Ag Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) * 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
BRPI0708004A2 (pt) 2006-01-30 2011-05-17 Platco Technologies Proprietary Ltd preparação de complexos de platina (ii)
KR100913063B1 (ko) 2006-09-13 2009-08-21 주식회사유한양행 옥살리플라틴-함유 주사용 용액
EP2124886A2 (en) * 2007-01-22 2009-12-02 Pliva-Lachema A.S. Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer
WO2009087660A1 (en) * 2007-11-12 2009-07-16 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
US20090130017A1 (en) * 2007-11-19 2009-05-21 Searete Llc Targeted short-lived drug delivery
TW201021855A (en) * 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
CN101461801B (zh) * 2008-12-26 2013-05-15 辰欣药业股份有限公司 一种奥沙利铂药物组合物及其制备方法
US9393201B2 (en) 2009-09-21 2016-07-19 Jw Pharmaceutical Corporation Oxaliplatin nanoparticles and method for preparing same
CN102274171A (zh) * 2011-08-04 2011-12-14 上海希迪制药有限公司 一种奥沙利铂注射剂
CN104523674B (zh) * 2014-12-11 2017-10-24 广州市上为医药科技有限公司 一种以奥沙利铂为主药成分的注射用组合物
KR101683635B1 (ko) * 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
CN104829653B (zh) * 2015-05-06 2016-03-23 山东罗欣药业集团股份有限公司 一种奥沙利铂水合物晶体及其冻干粉针剂
AU2019206492A1 (en) 2018-01-12 2020-07-16 Metimedi Pharmaceuticals Co., Ltd. Methods of treating chronic inflammatory diseases

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) * 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
PT93772A (pt) 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
KR920701221A (ko) 1989-12-15 1992-08-11 쓰무라 아끼라 신규한 백금 착체 및 이를 유효성분으로 하는 항종양제
JPH04185601A (ja) 1990-11-20 1992-07-02 Unitika Ltd 白金抗癌剤徐放性製剤
EP0612248B1 (en) 1991-11-15 2003-08-20 Smithkline Beecham Corporation Composition containing cisplatin and topotecan as antitumor agent.
JPH0776230B2 (ja) * 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JPH05238936A (ja) 1992-02-27 1993-09-17 Dainippon Pharmaceut Co Ltd カルシトリオールの水性液剤
JPH06287021A (ja) * 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
JP2673331B2 (ja) * 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
AU5416394A (en) * 1992-11-24 1994-06-22 Debiopharm S.A. Cisplatinum/oxaliplatinum combination
JP3025602B2 (ja) * 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
ES2152412T3 (es) * 1994-08-08 2001-02-01 Debiopharm Sa Preparacion farmaceuticamente estable de oxaliplatino.
ES2206478T3 (es) * 1994-11-11 2004-05-16 Debiopharm S.A. Composiciones carcinostaticas que contienen cis-oxaliplatino y otra u otras sustancias carcinostaticas compatibles.
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
EP0801070B1 (en) 1996-04-10 2003-04-16 Debiopharm S.A. Process of preparing platinum compound
JPH09294809A (ja) 1996-05-07 1997-11-18 Terumo Corp 薬液注入器具
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations

Also Published As

Publication number Publication date
EP0943331A3 (en) 1999-11-03
ATE202472T1 (de) 2001-07-15
ZA991489B (en) 1999-09-30
CN1291886A (zh) 2001-04-18
US6306902B1 (en) 2001-10-23
PT943331E (pt) 2001-12-28
NO329900B1 (no) 2011-01-24
MXPA00008195A (es) 2004-11-22
DK0943331T3 (da) 2001-10-15
GT199900019A (es) 2000-08-04
NO20004240L (no) 2000-10-18
HUP0103707A3 (en) 2004-07-28
JP2002504524A (ja) 2002-02-12
KR20010041182A (ko) 2001-05-15
HU224611B1 (hu) 2005-11-28
WO1999043355A3 (en) 1999-11-04
CN1152718C (zh) 2004-06-09
HK1036405A1 (en) 2002-01-04
HUP0103707A2 (hu) 2002-02-28
AU757101B2 (en) 2003-01-30
GR3036646T3 (en) 2001-12-31
NO20004240D0 (no) 2000-08-24
WO1999043355A2 (en) 1999-09-02
UA70316C2 (uk) 2004-10-15
CA2261500C (en) 2001-07-17
AR015524A1 (es) 2001-05-02
DE69900162T2 (de) 2002-04-18
CA2261500A1 (en) 1999-08-25
DE69900162D1 (de) 2001-08-02
EP0943331A2 (en) 1999-09-22
CZ302196B6 (cs) 2010-12-15
AU2632499A (en) 1999-09-15
EP0943331B1 (en) 2001-06-27
JP4430229B2 (ja) 2010-03-10
RU2207857C2 (ru) 2003-07-10
PL197948B1 (pl) 2008-05-30
IL137772A (en) 2006-04-10
CZ20003089A3 (cs) 2000-12-13
PL343021A1 (en) 2001-07-30
GB9804013D0 (en) 1998-04-22
BR9908273A (pt) 2000-10-24

Similar Documents

Publication Publication Date Title
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
PT758248E (pt) Formulacoes para o factor ix
UY27740A1 (es) Nuevos compuestos
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
HN2000000204A (es) Derivados de la purina
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
ECSP941104A (es) Derivados de 2,6 diaminopurina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2196377T3 (es) Derivados de naftiridina.
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ES2160680T3 (es) Utilizacion de un antagonista de sustancia p en una composicion farmaceutica.
ES2143734T3 (es) Compuestos bioaromaticos que llevan un grupo adamantilo en para, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
ES2157524T3 (es) Diselenuros y selenosulfuros utilizables como agentes antioxidantes.
MX9300399A (es) Derivados heterotriciclicos.
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o
AR025351A1 (es) Agonistas retinoides selectivos par
ES2052484T1 (es) N-(5-tioxo-l-prolil)-l-cisteina, sus derivados, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
ES2189072T3 (es) Nuevo benzo-cicloalquenos heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 943331

Country of ref document: ES